Tianjin Hongri Jiandakang Medical Technology

Hongri Jiandakang is a Chinese pharmaceutical company and a subsidiary of Tianjin Hongri Pharmaceutical Group, specializing in the development of innovative anti-cancer therapies. The company's flagship product is Toludesine (PTS), a first-in-class small molecule drug designed for intratumoral injection to treat various solid tumors. Toludesine received marketing approval from the NMPA in China for the treatment of severe airway obstruction in patients with advanced central non-small cell lung cancer. Beyond lung cancer, the company is exploring the drug's efficacy in esophageal, liver, and breast cancers. Hongri Jiandakang focuses on local chemical ablation as a therapeutic strategy to provide targeted treatment for malignant tumors.